Investigations

GRABAR LAW OFFICE INVESTIGATES CLAIMS AGAINST OFFICERS AND DIRECTORS OF AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM)

Axsome Therapeutics, Inc. is a biopharmaceutical company that engages in the development of novel therapies for CNS disorders in the U.S. The Company is developing, among other product candidates, AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine for the acute treatment of migraine.

An underlying securities fraud class action complaint alleges that Axsome Therapeutics (NASDAQ: AXSM), via certain of its officers, made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Axsome’s chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07 and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07’s regulatory and commercial prospects; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On March 31, 2025, the Court issued an Order denying Axsome's Motion to Dismiss. In doing so the court determined that the operative complaint sufficiently pleads material misrepresentations or omissions regarding two categories of statements: (1) Defendants’ statements that the manufacturing facility and suppliers for AXS-07 were not experiencing problems and (2) Defendants’ statements about AXS-07’s NDA.

If you purchased Axsome Therapeutics (NASDAQ: AXSM) prior to May 10, 2021 and still hold shares today, you are encouraged to contact Joshua Grabar at [email protected], or call 267-507-6085.  You may be able to seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.

 

Please enter your name.
Please enter a valid phone number.
Please enter a message.
Send

                                                                                           Attorney Advertising Disclaimer

Standard Derivative Form Retainer

Standard Form Derivative Retainer Letter - No Cost

  • Join This Action

  • Alternatively, you may upload your transactions using the upload button below or email them to [email protected]. *

  • Drop files here or
    Max. file size: 100 MB.
    • Clear Signature
      Signed pursuant to California Civil Code Section 1633.1, et seq. and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

    • Date of signing: *

    • MM slash DD slash YYYY
    • This field is for validation purposes and should be left unchanged.